Tema Oncology ETF
Tema Oncology ETF reported 59 holdings worth US$176M as of May 31, 2026 (Form N-PORT)
As of May 31, 2026 · Filed Jul 29, 2026
Tema Oncology ETF reported 59 holdings worth US$176M as of May 31, 2026. Largest: Revolution Medicines, Inc., Eli Lilly And Company and Roche Holding Ltd. Filed Jul 29, 2026 (Form N-PORT).
- Holdings
- 59
- Value as reported
- US$176M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Revolution Medicines, Inc. | 86,450 | US$13.6M | 7.7% |
| Eli Lilly And Company | 7,684 | US$8.49M | 4.8% |
| Roche Holding Ltd | 17,288 | US$7.42M | 4.2% |
| Cogent Biosciences, Inc. | 206K | US$7.22M | 4.1% |
| Novartis Ag | 47,020 | US$7.1M | 4.0% |
| Immunome, Inc. | 316K | US$6.89M | 3.9% |
| Celcuity Inc. | 47,450 | US$6.31M | 3.6% |
| Merck & Company, Inc. | 52,978 | US$6.29M | 3.6% |
| Astrazeneca Plc | 33,501 | US$6.23M | 3.5% |
| Nuvalent, Inc. | 53,763 | US$5.93M | 3.4% |
| Bristol-myers Squibb Company | 102K | US$5.81M | 3.3% |
| Abbvie Inc. | 22,700 | US$4.94M | 2.8% |
| Exelixis, Inc. | 96,885 | US$4.89M | 2.8% |
| Bridgebio Pharma, Inc. | 73,191 | US$4.85M | 2.8% |
| Johnson & Johnson | 19,900 | US$4.48M | 2.5% |
| Cg Oncology, Inc. | 68,702 | US$4.28M | 2.4% |
| Genmab A/s | 15,918 | US$4.18M | 2.4% |
| Ideaya Biosciences, Inc. | 136K | US$4M | 2.3% |
| Amgen Inc. | 11,019 | US$3.71M | 2.1% |
| Zai Lab Ltd. | 1.97M | US$3.48M | 2.0% |
| Beone Medicines Ltd. Class A | 11,505 | US$3.31M | 1.9% |
| Zymeworks Inc. | 106K | US$2.65M | 1.5% |
| Enliven Therapeutics, Inc. | 58,197 | US$2.3M | 1.3% |
| Relay Therapeutics, Inc. | 161K | US$2.26M | 1.3% |
| Halozyme Therapeutics, Inc. | 32,598 | US$2.17M | 1.2% |
| Summit Therapeutics Inc. | 121K | US$2.12M | 1.2% |
| Arcus Biosciences, Inc. | 83,140 | US$2.11M | 1.2% |
| Gilead Sciences, Inc. | 14,692 | US$1.98M | 1.1% |
| Immatics N.v. | 171K | US$1.97M | 1.1% |
| Erasca, Inc. | 148K | US$1.9M | 1.1% |
| Nuvation Bio Inc. | 395K | US$1.89M | 1.1% |
| Anaptysbio, Inc. | 31,270 | US$1.74M | 0.99% |
| Urogen Pharma Ltd. | 58,518 | US$1.65M | 0.93% |
| Guardant Health, Inc. | 10,986 | US$1.42M | 0.81% |
| Syndax Pharmaceuticals, Inc. | 72,212 | US$1.41M | 0.80% |
| Corvus Pharmaceuticals, Inc. | 108K | US$1.35M | 0.76% |
| Regeneron Pharmaceuticals, Inc. | 2,138 | US$1.31M | 0.75% |
| Arrivent Biopharma, Inc. | 42,744 | US$1.29M | 0.73% |
| Chugai Pharmaceutical Co., Ltd. | 23,697 | US$1.17M | 0.67% |
| Iovance Biotherapeutics, Inc. | 280K | US$1.15M | 0.65% |
| Inhibrx Biosciences, Inc. | 10,170 | US$1.06M | 0.60% |
| Olema Pharmaceuticals, Inc. | 79,759 | US$1.05M | 0.60% |
| Cullinan Therapeutics, Inc. | 62,826 | US$1.03M | 0.59% |
| Natera, Inc. | 4,238 | US$947K | 0.54% |
| First Tracks Biotherapeutics, Inc. | 58,419 | US$932K | 0.53% |
| Bridgebio Oncology Therapeutics, Inc. | 93,339 | US$837K | 0.48% |
| Cytomx Therapeutics, Inc. | 229K | US$824K | 0.47% |
| Hutchmed (china) Limited | 334K | US$777K | 0.44% |
| Arvinas, Inc. | 84,124 | US$755K | 0.43% |
| Janux Therapeutics, Inc. | 51,522 | US$752K | 0.43% |
| Tyra Biosciences, Inc. | 15,780 | US$527K | 0.30% |
| Oric Pharmaceuticals, Inc. | 57,977 | US$490K | 0.28% |
| Sellas Life Sciences Group, Inc. | 40,702 | US$379K | 0.22% |
| Monte Rosa Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Xencor, Inc. | 0 | US$0 | 0.00% |
| Terns Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Argenx Se | 0 | US$0 | 0.00% |
| Compass Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Nurix Therapeutics, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related